243 related articles for article (PubMed ID: 22658896)
1. Risk stratification of plasma cell neoplasm: insights from plasma cell-specific cytoplasmic immunoglobulin fluorescence in situ hybridization (cIg FISH) vs. conventional FISH.
Dong H; Yang HS; Jagannath S; Stephenson CF; Brenholz P; Mazumder A; Chari A
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):366-74. PubMed ID: 22658896
[TBL] [Abstract][Full Text] [Related]
2. Detection of chromosome abnormalities using cytoplasmic immunoglobulin staining and FISH in myeloma.
Mercer BR; Rayeroux KC
Methods Mol Biol; 2011; 730():159-71. PubMed ID: 21431641
[TBL] [Abstract][Full Text] [Related]
3. Modified cIg-FISH protocol for multiple myeloma in routine cytogenetic laboratory practice.
Gole L; Lin A; Chua C; Chng WJ
Cancer Genet; 2014; 207(1-2):31-4. PubMed ID: 24485403
[TBL] [Abstract][Full Text] [Related]
4. Targeting plasma cells improves detection of cytogenetic aberrations in multiple myeloma: phenotype/genotype fluorescence in situ hybridization.
Slovak ML; Bedell V; Pagel K; Chang KL; Smith D; Somlo G
Cancer Genet Cytogenet; 2005 Apr; 158(2):99-109. PubMed ID: 15796956
[TBL] [Abstract][Full Text] [Related]
5. Superior detection rate of plasma cell FISH using FACS-FISH.
Gagnon MF; Midthun SM; Fangel JA; Schuh CM; Luoma IM; Pearce KE; Meyer RG; Ailawadhi S; Arribas MJ; Braggio E; Fonseca R; Rajkumar SV; Zepeda-Mendoza C; Xu X; Greipp PT; Timm MM; Otteson GE; Shi M; Jevremovic D; Olteanu H; Peterson JF; Ketterling RP; Kumar S; Baughn LB
Am J Clin Pathol; 2024 Jan; 161(1):60-70. PubMed ID: 37658775
[TBL] [Abstract][Full Text] [Related]
6. Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization.
Chen L; Li J; Xu W; Qiu H; Zhu Y; Zhang Y; Duan L; Qian S; Lu H
Exp Oncol; 2007 Jun; 29(2):116-20. PubMed ID: 17704743
[TBL] [Abstract][Full Text] [Related]
7. Molecular cytogenetic aberrations in Tunisian patients with multiple myeloma identified by cIg-FISH in fixed bone marrow cells.
Gmidène A; Avet-Loiseau H; Sennana H; Ben Abdallah I; Khlif A; Meddeb B; Elloumi M; Saad A
Cytogenet Genome Res; 2012; 136(1):44-9. PubMed ID: 22188899
[TBL] [Abstract][Full Text] [Related]
8. Deletion(20q) as the sole abnormality in plasma cell myeloma is not associated with plasma cells as identified by cIg FISH.
White JS; Zordan A; Batzios C; Campbell LJ
Cancer Genet; 2012 Dec; 205(12):644-52. PubMed ID: 23200818
[TBL] [Abstract][Full Text] [Related]
9. Detection of chromosome 13q deletions and IgH translocations in patients with multiple myeloma by FISH: comparison with karyotype analysis.
Chang H; Li D; Zhuang L; Nie E; Bouman D; Stewart AK; Chun K
Leuk Lymphoma; 2004 May; 45(5):965-9. PubMed ID: 15291356
[TBL] [Abstract][Full Text] [Related]
10. Sequential analysis of chromosome aberrations in multiple myeloma during disease progression.
Wu KL; Beverloo B; Velthuizen SJ; Sonneveld P
Clin Lymphoma Myeloma; 2007 Jan; 7(4):280-5. PubMed ID: 17324335
[TBL] [Abstract][Full Text] [Related]
11. Genetic aberrations in multiple myeloma characterized by cIg-FISH: a Brazilian context.
Segges P; Braggio E; Minnicelli C; Hassan R; Zalcberg IR; Maiolino A
Braz J Med Biol Res; 2016; 49(5):e5034. PubMed ID: 27074166
[TBL] [Abstract][Full Text] [Related]
12. Interphase fluorescence in situ hybridization in multiple myeloma and monoclonal gammopathy of undetermined significance without and with positive plasma cell identification: analysis of 192 cases from the Region of Southern Denmark.
Christensen JH; Abildgaard N; Plesner T; Nibe A; Nielsen O; Sørensen AG; Kerndrup GB;
Cancer Genet Cytogenet; 2007 Apr; 174(2):89-99. PubMed ID: 17452249
[TBL] [Abstract][Full Text] [Related]
13. Chromosome 13q deletion and IgH abnormalities may be both masked by near-tetraploidy in a high proportion of multiple myeloma patients: a combined morphology and I-FISH analysis.
Koren-Michowitz M; Hardan I; Berghoff J; Yshoev G; Amariglio N; Rechavi G; Nagler A; Trakhtenbrot L
Cancer Lett; 2007 Oct; 255(2):307-14. PubMed ID: 17590504
[TBL] [Abstract][Full Text] [Related]
14. [High risk cytogenetic abnormalities in patients with multiple myeloma].
Legües ME; Morales P; Valenzuela M; Encina A; Martí MJ; Bascuñán C; Cornejo P; Peña C; Undurraga MS
Rev Med Chil; 2019; 147(1):61-64. PubMed ID: 30848766
[TBL] [Abstract][Full Text] [Related]
15. Fluorescent in situ hybridization studies in multiple myeloma.
Yuregir OO; Sahin FI; Yilmaz Z; Kizilkilic E; Karakus S; Ozdogu H
Hematology; 2009 Apr; 14(2):90-4. PubMed ID: 19298720
[TBL] [Abstract][Full Text] [Related]
16. Cytoplasmic Immunoglobulin Light Chain Revelation and Interphase Fluorescence In Situ Hybridization in Myeloma.
Moore S; Suttle JM; Nicola M
Methods Mol Biol; 2017; 1541():127-142. PubMed ID: 27910020
[TBL] [Abstract][Full Text] [Related]
17. Array-based karyotyping in plasma cell neoplasia after plasma cell enrichment increases detection of genomic aberrations.
Zehentner BK; Hartmann L; Johnson KR; Stephenson CF; Chapman DB; de Baca ME; Wells DA; Loken MR; Tirtorahardjo B; Gunn SR; Lim L
Am J Clin Pathol; 2012 Oct; 138(4):579-89. PubMed ID: 23010713
[TBL] [Abstract][Full Text] [Related]
18. Detection of chromosome 13 deletions by fluorescent in situ hybridization.
VanWier S; Fonseca R
Methods Mol Med; 2005; 113():59-69. PubMed ID: 15968095
[TBL] [Abstract][Full Text] [Related]
19. [Investigation of 1q21 amplification in patients with multiple myeloma using I-FISH and cIg-FISH].
Yang RF; Li CM; Qiu HR; Lu H; Wu HX; Xu JR; Zhang P; Li JY; Chen LJ
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2011 Dec; 28(6):686-9. PubMed ID: 22161106
[TBL] [Abstract][Full Text] [Related]
20. The success rate of interphase fluorescence in situ hybridization in plasma cell disorders can be improved using unconventional sources of plasma cells.
Panakkal V; Rana S; Rathore S; Anshu A; Balakrishnan A; Singh C; Jandial A; Sachdeva MUS; Varma N; Lad D; Malhotra P; Sreedharanunni S
Int J Lab Hematol; 2022 Feb; 44(1):157-162. PubMed ID: 34636141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
